STOP Heart Disease in Breast Cancer Survivors Trial

Inclusion Criteria: * Female patients with newly diagnosed stage 1-3 breast cancer * Histologically confirmed HER2, ER, and PR status * Recommended to undergo trastuzumab treatment, with or without anthracycline. Patients will be eligible for up to 3 weeks after starting treatment. * Age minimum 18 years * Able and willing to read, understand, and sign an informed consent form (ICF) and medical release form * Willing and able to comply with trial protocol and follow-up * ECOG performance status 0-1 (Karnofsky ≥ 70%) Exclusion Criteria: * Prior use of statin medication within the past year * Not using statin medication but is eligible for statin therapy based on the 2013 ACC/AHA guidelines (LDL cholesterol \>190, or LDL \<190 and ASCVD risk \>7.5%; http://tools.acc.org/ASCVD-Risk-Estimator/) and is \> 50 years old; or is eligible for statin therapy based on the 2013 ACC/AHA guidelines and is 40-50 years old and wishes to be placed on statin therapy * History of adverse effects, intolerance, or allergic reactions attributed to statin medication * Current use of gemfibrozil, cyclosporine, clarithromycin, itraconazole, erythromycin, the hepatitis C protease inhibitor telaprevir, HIV protease inhibitors, colchicine, or red yeast rice * Current use of any other investigational agent * Pregnant or intention to get pregnant during the next 18 months. Pregnant women are excluded from this study because atorvastatin is a lipid-lowering agent with the potential for teratogenic or abo…